Core Insights - Dingdang Health Technology Group has partnered with Eli Lilly to launch Tirzepatide injection (Mounjaro) in pharmacies in Guangzhou and Shenzhen, following its initial rollout in Beijing [2] - The collaboration aims to provide a one-stop health solution for overweight/obese and diabetic populations, enhancing medication accessibility and health management [2] - Eli Lilly is recognized as a leading global pharmaceutical company with significant achievements in diabetes, obesity, Alzheimer's disease, immune disorders, and oncology [2] - Dingdang Health is focused on building a smart health service platform and enhancing digital service capabilities, establishing four smart warehouses nationwide and strengthening cold chain delivery services in major cities [2] - The partnership is expected to improve the accessibility of original research drugs in the Chinese market, benefiting local patients [3] Company and Industry Developments - Dingdang Health is enhancing its supply chain and digital service levels to create an integrated management model combining instant drug retail, health education, and digital services [2] - The launch of the "Original Drug Supply Alliance" by Dingdang Health aims to meet diverse medication needs and expand the availability of original research drugs in China [3]
叮当健康加码“创新药”布局 与礼来达成合作